Lifecore Biomedical, Inc. (LFCR) Dividend History

Company News

• Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

  Humanetics, a pharmaceutical company, has selected Lifecore Biomedical, a contract development and manufacturing organization, to provide services to support the development of BIO 300, a drug for preventing acute radiation syndrome. The collaboration will involve technology transfer, formulation development, and analytical method work.

  GlobeNewswire Inc.
• Lifecore Biomedical Announces Special Stockholder Meeting

  Lifecore Biomedical, Inc. (LFCR) is seeking shareholder approval to remove the convertible preferred stock exchange cap, which would allow for potential conversion of its Series A Preferred Stock beyond the current limit.

  GlobeNewswire Inc.
• Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

  Lifecore Biomedical, a contract development and manufacturing organization, has sold its 10-head filler for $17 million to a non-competitive buyer. The company believes it is well-positioned for mid-term and long-term growth as its current capacity can support up to $300 million in annual revenue.

  GlobeNewswire Inc.
• US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus

  U.S. stock futures were higher on Friday, with the S&P 500 and Nasdaq Composite indices slipping in the previous session. Tesla, Bumble, and Lifecore Biomedical were in focus.

  Benzinga

  Featured Companies: BMBL TSLA
• Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024

  Lifecore Biomedical, a contract development and manufacturing organization, announced that it will host a virtual investor day on November 21, 2024, where the company's senior management team will discuss its business and growth strategy.

  GlobeNewswire Inc.